- Home
- SBLK vs NMRA Comparison
SBLK vs NMRA Comparison
Compare SBLK & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- NMRA
- Stock Information
- Founded
- SBLK 2006
- NMRA 2019
- Country
- SBLK Greece
- NMRA United States
- Employees
- SBLK N/A
- NMRA N/A
- Industry
- SBLK Marine Transportation
- NMRA
- Sector
- SBLK Consumer Discretionary
- NMRA
- Exchange
- SBLK Nasdaq
- NMRA Nasdaq
- Market Cap
- SBLK 1.8B
- NMRA 1.7B
- IPO Year
- SBLK N/A
- NMRA 2023
- Fundamental
- Price
- SBLK $14.68
- NMRA $2.06
- Analyst Decision
- SBLK Strong Buy
- NMRA Strong Buy
- Analyst Count
- SBLK 3
- NMRA 6
- Target Price
- SBLK $25.00
- NMRA $20.67
- AVG Volume (30 Days)
- SBLK 1.8M
- NMRA 6.2M
- Earning Date
- SBLK 02-10-2025
- NMRA 03-06-2025
- Dividend Yield
- SBLK 16.44%
- NMRA N/A
- EPS Growth
- SBLK 10.39
- NMRA N/A
- EPS
- SBLK 2.98
- NMRA N/A
- Revenue
- SBLK $1,220,003,000.00
- NMRA N/A
- Revenue This Year
- SBLK $17.35
- NMRA N/A
- Revenue Next Year
- SBLK $7.09
- NMRA N/A
- P/E Ratio
- SBLK $4.92
- NMRA N/A
- Revenue Growth
- SBLK 24.41
- NMRA N/A
- 52 Week Low
- SBLK $14.37
- NMRA $1.83
- 52 Week High
- SBLK $27.47
- NMRA $21.00
- Technical
- Relative Strength Index (RSI)
- SBLK 36.21
- NMRA 20.38
- Support Level
- SBLK $14.91
- NMRA $2.00
- Resistance Level
- SBLK $15.58
- NMRA $2.44
- Average True Range (ATR)
- SBLK 0.43
- NMRA 0.35
- MACD
- SBLK 0.10
- NMRA -0.21
- Stochastic Oscillator
- SBLK 23.66
- NMRA 2.38
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.